Teladoc (TDOC) Form 144 Notices Restricted Stock Sale of 5,867 Shares

Rhea-AI Filing Summary

Teladoc Health, Inc. (TDOC) Form 144 shows an insider sale notice for 5,867 common shares, with an aggregate market value of $44,502.95, reported for an approximate sale date of 09/02/2025 on the NYSE. The shares were acquired by restricted stock vesting on 08/29/2025 and are being sold as compensation. The filer also reported a prior sale of 5,808 shares on 06/02/2025 for gross proceeds of $39,842.88. Outstanding shares are listed as 176,690,662, indicating the disclosed transactions represent a very small fraction of total shares.

Positive

• Disclosed acquisition source: Securities were acquired via restricted stock vesting on 08/29/2025, clarifying the origin of the shares.
• Regulatory compliance: The filer submitted Form 144 as required and represented no undisclosed material adverse information, supporting transparency.

Negative

• Insider sale reported: The notice records a planned sale of 5,867 shares (and a prior sale of 5,808 shares), which are dispositions by an insider even though amounts are small.

Insights

Securities Analyst

TL;DR: Small insider sale from vested restricted stock; immaterial to capitalization but important for disclosure transparency.

The Form 144 documents an intended sale of 5,867 shares valued at $44,502.95 arising from restricted stock vesting dated 08/29/2025. Given total shares outstanding of 176,690,662, the transaction is immaterial to overall market capitalization. The filing fulfils Rule 144 notice requirements and clarifies that the acquisition was compensation-related rather than an open-market purchase, which is relevant when assessing insider motivations. Prior sale activity (5,808 shares on 06/02/2025) is disclosed, indicating recurring small dispositions. Impact on share supply and liquidity is negligible.

Corporate Governance Expert

TL;DR: Proper disclosure of equity compensation vesting and planned sale; governance practice aligns with Rule 144 compliance.

The filer certified absence of undisclosed material adverse information and provided required details including acquisition date, nature (restricted stock vesting), and payment nature (compensation). This transparency supports good governance and regulatory compliance. The size of the proposed sale is small relative to outstanding shares, suggesting limited governance or control implications. The filing does not disclose any trading-plan adoption date or 10b5-1 plan details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5867	44502.95	176690662	09/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Restricted Stock Vesting	Issuer			5867	08/29/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Adam Vandervoort 155 E 44th Street Floor 17 New York NY 10017	Common	06/02/2025	5808	39842.88

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TDOC Form 144 report from this filing?

The filing reports an intended sale of 5,867 common shares valued at $44,502.95, with an approximate sale date of 09/02/2025, to be executed on the NYSE.

How were the shares acquired according to the filing?

The shares were acquired by restricted stock vesting on 08/29/2025, and the nature of payment is listed as compensation.

Did the filer sell any TDOC shares in the past three months?

Yes. The filing discloses a prior sale of 5,808 common shares on 06/02/2025 for gross proceeds of $39,842.88.

How material is the reported sale relative to TDOC's outstanding shares?

With 176,690,662 shares outstanding, the reported sale represents a very small fraction of total shares, indicating immaterial impact on capitalization.

Does the filing indicate a 10b5-1 trading plan or plan adoption date?

No. The filing does not state any 10b5-1 trading plan adoption date or provide trading-plan details.